Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 133 locations and has been updated from revision v2.9.7 to v2.10.0.
    Difference
    0.3%
    Check dated 2024-07-23T15:55:13.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T09:29:55.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T15:40:03.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T11:31:14.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T10:14:50.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Revision: v2.9.0' has been updated to 'Genetic and Rare Diseases Information Center resources: Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma Drug Information available for: Cabozantinib FDA Drug and Device Resources'. This change reflects an update in the information provided on the webpage related to the study.
    Difference
    29%
    Check dated 2024-06-25T09:15:30.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.